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Abstract
Background and Objectives Morquio A syndrome
(mucopolysaccharidosis IVA; MPS IVA) is a lysosomal
storage disorder caused by deficiency of N-acetyl-
galactosamine-6-sulfatase, an enzyme required for degra-
dation of the glycosaminoglycan keratan sulfate. Enzyme
replacement therapy with elosulfase alfa provides a
potential therapy for Morquio A syndrome. We analyzed
the pharmacokinetics and pharmacodynamics of elosulfase
alfa in Morquio A patients from a phase III clinical trial.
Methods In a randomized double-blind study, elosulfase
alfa at 2.0 mg/kg was administrated weekly or every other
week for 24 weeks. Pharmacokinetic parameters of elo-
sulfase alfa were determined at weeks 0 and 22 by non-
compartmental analysis. Safety was assessed throughout
the study. The relationship of pharmacokinetic parameters
to patient demographics, pharmacodynamic assessments,
immunogenicity, and efficacy and safety outcomes were
assessed graphically by treatment group.
Results Elosulfase alfa exposure and half-life (t)
increased for both dose regimens during the study. There
appeared to be no consistent trend between drug clearance
(CL) and patient’s sex, race, body weight, or age. All
patients developed anti-drug antibodies, but no association
was noted between total antibody titer and CL. In contrast,
positive neutralizing antibody (NAb) status appeared to
associate with decreased CL and prolonged t for patients
in the cohort dosed weekly. NAb may interfere with
receptor-mediated cellular uptake and lead to increased
circulation time of elosulfase alfa.
Conclusion Despite the association between NAb and
decreased drug clearance, neither dosing cohort showed
associations between drug exposure and change in urinary
keratan sulfate, 6-min walk test distances, or the occur-
rence of adverse events.
Key Points
Elosulfase alfa is an enzyme replacement therapy for
Morquio A syndrome that was evaluated in patients
with Morquio A syndrome
Neutralizing anti-elosulfase alfa antibodies may
interfere with elosulfase alfa uptake from plasma
into cells
No associations were apparent between
pharmacokinetic parameters and changes in urine
keratan sulfate levels, the pharmacodynamic readout
Variability in elosulfase alfa exposure in plasma may
not translate directly to pharmacodynamic, efficacy
or safety outcomes in patients.
1 Introduction
Morquio A syndrome (mucopolysaccharidosis IV A; MPS
IVA; OMIM 253000) is an autosomal, recessive, lysosomal
storage disease caused by a deficiency of N-acetyl-
galactosamine-6-sulfatase (GALNS; EC 3.1.6.4), an
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enzyme required for degradation of the glycosaminogly-
cans (GAGs) chondroitin-6-sulfate and keratan sulfate
(KS). Morquio A syndrome is rare, with an incidence
estimated to range from 1 in 76,000 to 1 in 640,000 live
births in different populations [1–3].
Patients with Morquio A syndrome appear healthy at
birth but develop multiple clinical signs owing to the
accumulation of GAGs causing cellular disruptions in
multiple cells, tissues, and organs. The progress of the
disease and the severity of individual clinical manifesta-
tions can vary considerably between patients. Prominent
skeletal and connective tissue abnormalities are common,
with patients often manifesting dwarfism with short trunk
and neck, spinal abnormalities, genu valgum, pectus car-
inatum, hip dysplasia, and joint instability and hypermo-
bility as a result of ligamentous laxity and joint bone
deformities [4]. Pulmonary and cardiac manifestations are
also common, which can result in reduced endurance and
impact both quality of life and mortality; death often
results from cardiorespiratory or neurological complica-
tions [4]. Patients with slowly progressing disease rarely
survive their sixth decade, and patients with rapidly pro-
gressing disease often die in their second or third decade
[4].
Enzyme replacement therapy (ERT) by intravenous
infusion of recombinant human GALNS (elosulfase alfa;
VimizimTM, BioMarin Pharmaceutical Inc., Novato, CA,
USA) is approved by the US Food and Drug Adminis-
tration for treatment of patients with Morquio A syn-
drome. Elosulfase alfa is expected to increase the
degradation of accumulated KS and chondroitin-6-sulfate
that cause the Morquio A clinical manifestations. The
MOR-004 phase III study was designed to assess the
safety and efficacy of two different elosulfase alfa dosing
regimens, 2.0 mg/kg every other week (QOW) and
2.0 mg/kg weekly (QW), in comparison with placebo [5].
The elosulfase alfa dose level of 2.0 mg/kg was chosen
based on prior in vitro analysis in a human cell culture
model of Morquio A syndrome [6] and a prior phase 1/2
dose-escalation study in patients with Morquio A syn-
drome [7]. Results from the phase I–II study indicated that
elosulfase alfa had a short plasma elimination half-life of
about 40 min following repeat intravenous infusion and
that increases in the area under the plasma concentration-
time curve from time zero to the time of last measurable
concentration (AUClast) and the maximum concentration
in plasma (Cmax) were greater than dose proportional
when the dose was increased from 1.0 to 2.0 mg/kg/week
[8]. Here, we report the pharmacokinetic and pharmaco-
dynamic results of elosulfase alfa in patients with Morquio
A syndrome from the pivotal phase III trial.
2 Methods
2.1 Study Design and Patients
Data from the MOR-004 study served as the basis for this
analysis [5]. In brief, MOR-004 was a phase III, random-
ized, double-blind, placebo-controlled study of elosulfase
alfa in patients with Morquio A syndrome over 24 weeks,
conducted at 33 study centers in 17 countries. The study
protocol was approved by an Institutional Review Board,
Independent Ethics committee, or Research Ethics Board at
each participating clinical site. Each participant or his/her
legally authorised representative provided written informed
consent before entering the study. Patients, investigators,
and site personnel were blinded to treatment assignments
until the final analysis was complete.
All study participants had a documented clinical diag-
nosis of Morquio A syndrome based on clinical signs and
symptoms, together with either a documented decrease in
GALNS enzyme activity as assayed in fibroblasts or leu-
kocytes or a genetic test confirming the Morquio A diag-
nosis [5].
A total of 176 patients entered the study, of whom 59
were randomized to placebo, 59 to receive elosulfase alfa
2.0 mg/kg every other week (QOW), and 58 to receive
elosulfase alfa 2.0 mg/kg weekly (QW); one patient from
the QW group discontinued the study. As the study was
conducted in a blinded manner, samples for pharmacoki-
netic analysis were collected from 65 patients (17 receiving
placebo, 24 receiving elosulfase alfa 2.0 mg/kg/QOW, and
24 receiving elosulfase alfa 2.0 mg/kg/QW); pharmacoki-
netic parameters were estimated only for the 48 patients
receiving elosulfase alfa.
2.2 Administration of Elosulfase Alfa
To reduce the risk of potential infusion-associated reac-
tions, patients were pretreated with an antihistamine at
approximately 30–60 min prior to infusion. At the dis-
cretion of the investigator, patients with known risk fac-
tors for infusion-associated reactions could receive
additional agents prior to infusion, such as a sedating
antihistamine (e.g., diphenhydramine or chlorphenir-
amine), H2-receptor blockers, montelukast sodium, or
steroids. Elosulfase alfa (2.0 mg/kg) or placebo solution
was diluted with saline to a final volume of 250 mL,
allowed to reach room temperature, and was administered
intravenously. Patients randomized to the QOW group
received infusions of elosulfase alfa or placebo on alter-
nating weeks. Each infusion was administered over
approximately 4 h.
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2.3 Pharmacokinetic Analysis
Blood samples for pharmacokinetic analysis were drawn at
weeks 0 and 22 from an IV line separate from that for
infusion. Samples were drawn predose (within 15 min
prior to dosing), 60 and 120 min after beginning infusion,
within 5 min prior to ending the infusion, and then at 5, 15,
30, 60, 120, and 180 min postinfusion. Because of missing
samples one patient was excluded from pharmacokinetic
analysis, two patients (from QOW and QW cohorts) lacked
pharmacokinetic values at week 22, and one patient (QW
cohort) lacked pharmacokinetic values at week 0. Plasma
elosulfase alfa concentrations were measured by a vali-
dated electrochemiluminescence (ECL) assay using a
sandwich format (Supplementary Methods S1.1). The lower
limit of quantitation for elosulfase alfa was 15.6 ng/mL. The
in-study inter-assay accuracy (% relative error) and precision
(% coefficient of variation, CV) did not exceed 12.0 %
(BioMarin, unpublished results).
Pharmacokinetic parameters of elosulfase alfa were
estimated based on the plasma concentration–time data
using Phoenix WinNonlin 6.1 (Pharsight Corporation,
Cary, NC, USA) by non-compartmental analysis. Because
the elosulfase alfa mean elimination half-life (t) is short
(mean t\1 h) relative to its dosing interval (1 or
2 weeks), each infusion was treated as a single dose for
pharmacokinetic analysis. Maximum concentration in
plasma (Cmax) and the time of maximum concentration
(tmax) were recorded directly from the observed data. Other
pharmacokinetic parameters estimated in this study include
t, area under the plasma concentration–time curve from
time 0 to the last measurable concentration, estimated by
linear trapezoidal rule (AUClast), area under the plasma
concentration–time curve extrapolated to infinity (AUC0–?),
clearance of the absorbed fraction (CL), volume of distribu-
tion based on terminal phase (Vz), and volume of distribution
at steady state (Vss).
2.4 Efficacy and Safety Evaluations
The primary endpoint of the study was the distance trav-
eled during a 6-min walk test (6MWT), a test of endurance
that was performed based on American Thoracic Society
guidelines [9]. The secondary efficacy endpoints were the
number of stairs climbed per minute in the 3-min stair
climb test (3MSCT) and the urinary keratan sulfate (uKS)
normalized to creatinine [5].
Safety was assessed by examining the incidence,
severity, and relationship to the study drug of treatment-
emergent adverse events (AEs) reported during the study
[5]. Additionally, infusion-associated reactions, laboratory
results, vital signs, physical examination results, and
medication use were assessed. Electrocardiograms and
echocardiograms were performed at baseline and at week
24. Immunogenicity was also assessed (see Sect. 2.6;
unpublished data, BioMarin Pharmaceutical Inc). Potential
hypersensitivity AEs were identified by using the stan-
dardized Medical Dictionary of Regulatory Activities
(MedDRA, version 15.0) queries for broad anaphylactic
reaction and broad angioedema [5]. Full safety data from
this study were published elsewhere [5]; in brief, in the
QW dosing cohort 22.4 % of patients had AEs that led to
an elosulfase alfa infusion interruption or discontinuation
that required medical intervention, but for both dosing
groups no AEs led to permanent treatment discontinuation
[5].
2.5 Pharmacodynamic Efficacy
Urinary keratan sulfate was quantitatively measured by
keratanase II digestion followed by liquid chromatography
and tandem mass spectrometry (LC-MS/MS) analysis of
samples obtained from first morning voids on two separate
days at baseline, and then at weeks 2 and 4, then every
4 weeks thereafter, as well as within 1 week of an early
withdrawal. The measured concentrations of the two major
KS disaccharides generated by digestion were summed and
normalized to urine creatinine concentrations [5] (Supple-
mentary Methods S1.2). Assay sensitivity was 0.104 lg/mL
for each disaccharide and in-study between-run precision
was less than 9 % CV [5].
2.6 Immunogenicity Analysis
Serum samples were collected at baseline, at weeks 2 and
4, and every 4 weeks thereafter, and within 1 week of an
early-termination visit. Samples for immunogenicity test-
ing were drawn prior to administration of elosulfase alfa or
placebo. Total elosulfase alfa-specific antibody (TAb) and
neutralizing elosulfase alfa-specific antibody (NAb) were
evaluated by validated ECL bridging and fluorescence
competition ELISA assays, respectively. NAb, which is a
subset of TAb, was not assessed if TAb was negative.
The total antibody assay measures multiple anti-drug
antibody isotypes in a single assay. TAb-positive samples
were confirmed for elosulfase alfa specificity and serially
diluted to obtain a titer (Supplementary Methods S1.3).
The validated NAb assay detects antibodies capable of
inhibiting elosulfase alfa from binding to plate-immobi-
lized cation-independent mannose-6-phosphate receptor
(CI-M6PR) and produces a qualitative assessment of
positive or negative (Supplementary Methods S1.4). The
in-study between-run precision was below 17 % (TAb) and
28 % (NAb) CV, consistent with assay validation perfor-
mance (BioMarin unpublished results). As elosulfase alfa
is active in the acidic environment of the lysosome and not
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the neutral pH of blood, no assay was developed to detect
antibodies that inhibit enzymatic activity.
2.7 Statistical Analyses
Demographic characteristics were summarized for the
pharmacokinetic population. Pharmacokinetic parameters
were summarized descriptively for weeks 0 and 22 and by
treatment group. As analyses of the pharmacokinetic pop-
ulation were not powered to assess statistical significance,
the relationship of pharmacokinetic parameters to demo-
graphic characteristics, immunogenicity, pharmacody-
namics, efficacy, and AE parameters were assessed
graphically by treatment group.
3 Results
3.1 Patient Characteristics
In the MOR-004 trial, patients with Morquio A syndrome
were randomized to receive placebo, elosulfase alfa
2.0 mg/kg/QW, or elosulfase alfa 2.0 mg/kg/QOW. The
demographic characteristics of the pharmacokinetic ana-
lysis population were generally comparable between those
receiving elosulfase alfa QW and QOW (Supplemental
Table S1) with the exception of sex: the QW pharmaco-
kinetic population was 60.9 % female (14/23) and the
QOW pharmacokinetic population was 25.0 % female (6/
24). Demographic characteristics and baseline character-
istics for patients who were included in the pharmacoki-
netic analysis (Supplemental Table S1) were similar to
those of the general study population [5].
3.2 Pharmacokinetics
Elosulfase alfa was administered as an infusion, typically
over 4 h. The mean plasma concentration of elosulfase alfa
during and after infusion is shown in Fig. 1, at the initial
infusion (week 0) and at week 22 for both dosing cohorts.
At both weeks 0 and 22 and in both dosing cohorts, elo-
sulfase alfa was detectable in plasma at the first time point
after beginning infusion (60 min) and reached maximum
concentrations between 120 and 240 min. After 240 min,
the typical endpoint for elosulfase alfa infusions, plasma
elosulfase alfa concentration decreased with time. The
pharmacokinetic parameters were comparable between the
dosing cohorts at week 0 but differed at week 22 (Table 1).
At week 0, the t was *7 min for both dosing cohorts, but
Fig. 1 Mean plasma concentration profiles of elosulfase alfa during
and after infusion. Mean plasma concentration of elosulfase alfa
during and after infusion is displayed with standard error bars at
nominal pharmacokinetic sampling time for weeks 0 and 22 and by
treatment group. Time scale is nominal time, with 0 min the
beginning of infusion and 240 min the typical infusion end point.
QOW every other week, QW weekly
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at week 22 the QOW cohort had a t of *19 min and the
QW cohort had a t of *36 min. For the QOW cohort,
exposure increased by 76 or 84 %, as measured by AUClast
or Cmax, respectively, between weeks 0 and 22, and for the
QW cohort, exposure increased by 181 or 192 % (by
AUClast or Cmax, respectively).
3.3 Pharmacokinetics and Patient Demographics
The relationship between the demographic characteristics
of patients included in the pharmacokinetic analysis and
the pharmacokinetic results were examined to determine if
pharmacokinetics of elosulfase alfa were influenced by









AUC 0–?, ngmin/mL 287,597 (96,432.1), 14 231,074 (103,207.4), 15 124.5
AUClast, ngmin/mL 248,720 (97,063.7), 24 237,884 (100,328.6), 22 104.6
Cmax, ng/mL 1,438 (435.3), 24 1,494 (534.1), 22 96.2
CL, mL/min/kg 7.54 (2.002), 14 10.04 (3.733), 15 75.1
Vss, mL/kg 219.42 (95.483), 12 395.74 (315.636), 14 55.4
Vz, mL/kg 68.79 (34.008), 14 123.66 (144.115), 15 55.6
t, min 6.57 (3.110), 14 7.52 (5.484), 15 87.4
tmax, min 150 (58.1), 24 172 (75.3), 22 87.2
Week 22
n 23 22
AUC 0–?, ngmin/mL 463,460 (491,418.9), 19 619,080 (422,048.3), 20 74.9
AUClast, ngmin/mL 411,687 (420,279.7), 23 577,371 (416,316.6), 22 71.3
Cmax, ng/mL 2,616 (2,702.1), 23 4,036 (3,237.1), 22 64.8
CL, mL/min/kg 6.50 (2.942), 19 7.08 (12.997), 20 91.8
Vss, mL/kg 245.19 (273.145), 17 649.67 (1,841.703), 20 37.7
Vz, mL/kg 120.11 (71.076), 19 299.52 (543.309), 20 40.1
t, min 19.25 (19.217), 19 35.86 (21.485), 20 53.7
tmax, min 159 (60.6), 23 202 (90.8), 22 78.5
Week 22/Week 0b (%)
n 23 21
AUC 0–?, ngmin/mL 179.2 328.6
AUClast, ngmin/mL 176.3 280.6
Cmax, ng/mL 183.6 291.6
CL, mL/min/kg 87.0 46.4
Vss, mL/kg 127.0 188.9
Vz, mL/kg 147.0 246.0
t, min 280.0 696.0
tmax, min 119.8 145.7
Values are expressed as mean (SD), n unless otherwise indicated
For patients who have missing values of AUC0–?, t, CL, Vz and Vss, the parameters could not be estimated due to insufficient data in the
terminal phase of the plasma profile. For patients who have missing values of Vss only, their Vss was not reported due to a negative value.
Adjusting for infusion caused a negative MRTinf value. The Vss value was also negative because of the relationship: Vss = MRTinfCL
AUC0–? area under the plasma concentration–time curve from time zero to infinity, AUClast area under the plasma concentration–time curve
from time zero to the time of last measurable concentration, CL total clearance of drug after intravenous administration, Cmax observed maximum
plasma concentration, MRTinf mean residence time extrapolated to infinity, SD standard deviation, QOW every other week, QW weekly, Vss
apparent volume of distribution at steady-state, Vz apparent volume of distribution based upon the terminal phase, t elimination half-life
a Ratio is ratio of means
b Only patients with pharmacokinetic data available for both visits are included
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demographics. Male and female patients had comparable
clearance of elosulfase alfa at both weeks 0 and 22 (Fig. 2).
At week 0, white patients (n = 20) had higher elosulfase
alfa clearance than non-white patients (n = 9; Fig. 2a), but
this trend was not observed at week 22 (Fig. 2b, c). At
week 0, patients with increased body weight and increased
age showed decreased clearance of elosulfase alfa
(Fig. 2a), but neither trend was observed at week 22
(A)
(B)




(a) week 0; (b) week 22, QOW
dosing group; (c) week 22, QW
dosing group. CL total clearance
of drug after intravenous
administration, QOW every
other week, QW weekly. The
bottom and top of whiskers
represents the minimum and
maximum values excluding
outliers, which are plotted
separately. The lower and upper
ends of the box represent the
first and third quartile, the bar
within the box represents the
median value and the diamond
within the box represents the
mean value
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(Fig. 2b, c). The relationships between the pharmacoki-
netic parameters AUClast, AUC0–?, Cmax, Vss, and t and
patient demographic characteristics were also examined
and no consistent relationships were observed (data not
shown).
3.4 Immunogenicity and Pharmacokinetics
All patients treated with elosulfase alfa were positive for
total antibody against elosulfase alfa (TAb) by week 24
(unpublished data, BioMarin Pharmaceutical Inc). Given
the immunogenicity of elosulfase alfa, the relationship
between immunogenicity and pharmacokinetic parameters
was examined to determine if the pharmacokinetics of el-
osulfase alfa was influenced by development of anti-drug
antibodies. TAb titers at week 24 were plotted against el-
osulfase alfa CL at week 22 (Fig. 3a) and no general
association was observed between TAb titer and CL for
either dosing group. Similarly, TAb titers at week 24 were
plotted against elosulfase alfa mean t at week 22, and no
general association was observed between TAb titer and
mean t for either group (Fig. 3b).
The mean elosulfase alfa CL at week 22 was compared
between patients either positive or negative for NAb at week
24 (Fig. 3a). For patients in the QOW cohort, there was little
difference in mean CL between NAb-negative patients (n = 4/
19) and NAb-positive patients (n = 15/19; mean difference
CL 0.35 mL/min/kg; 95 % CI -3.24 to 3.94), but for patients
in the QW cohort, NAb-negative patients (n = 2/19) had
higher mean CL than NAb-positive patients (n = 17/19; mean
difference CL 3.65 mL/min/kg; 95 % CI 0.37–6.93). Similarly,
when the mean elosulfase alfa t was compared between NAb-
negative and NAb-positive patients (Fig. 3b), in the QOW
cohort, there was little difference in mean t between NAb-
negative patients (n = 4/19) and NAb-positive patients
(n = 15/19; mean difference t -16.11 min; 95 % CI -38.1
to 5.87 min), but in the QW cohort, NAb-negative patients
(n = 2/20) had decreased mean t compared with NAb-posi-
tive patients (n = 18/20; mean difference t -33.03 min;
95 % CI -63.5 to -2.58 min).
3.5 Pharmacokinetics/Pharmacodynamics and Efficacy
The overall pharmacodynamic results of this study were
reported elsewhere [5]; in brief, both QW and QOW dosing
of elosulfase alfa led to reductions in uKS when compared
with placebo. To evaluate whether the variability in patient
pharmacodynamics was related to elosulfase alfa exposure
(as measured either by AUClast or Cmax in plasma), levels
of uKS from patients with Morquio A syndrome were
assessed over time and compared with elosulfase alfa
exposure (Fig. 4). No relationship between exposure to
elosulfase alfa at week 22 and patients’ change in uKS
between weeks 0 and 24 was observed.
(C)
Fig. 2 continued
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The overall efficacy findings of this study were reported
elsewhere [5]. In brief, QW dosing of elosulfase alfa led to
statistically significant improvements in 6MWT distances
vs. placebo but QOW dosing did not, and neither QW nor
QOW dosing was associated with statistically significant
improvements in 3MSCT results. Here, the relationship
between patients’ exposures and efficacy outcomes was
examined (Supplementary Figure S1, Supplementary Fig-
ure S2). For patients in both the QOW and QW cohorts,
exposure at week 22 (as measured by either AUClast or
Cmax in plasma) showed no evident association with
changes in 6MWT or 3MSCT between weeks 0 and 24
(Supplementary Figure S1, Supplementary Figure S2).
3.6 Pharmacokinetics and Adverse Events
The occurrence of AEs [5] was analyzed against elosulfase
alfa exposure (AUClast and Cmax); the results indicated no
(A)
(B)





from week 22 and patient
immunogenicity status is from
week 24. a Elosulfase alfa
clearance and immunogenicity.
b Elosulfase alfa plasma
elimination half-life and
immunogenicity. The bottom
and top of whiskers represents
the minimum and maximum
values excluding outliers, which
are plotted separately. The
lower and upper ends of the box
represent the 1st and 3rd
quartile, the bar within the box
represents the median value and
the diamond within the box
represents the mean value. CL
total clearance of drug after
intravenous administration, NAb
neutralizing elosulfase alfa-
specific antibodies that inhibit
cellular receptor binding, TAb
total anti-elosulfase alfa
antibody, QOW every other
week, QW every week
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substantial differences between patients with and without
AEs (Supplementary Figure S3). In addition, increase in
elosulfase alfa exposure (AUClast and Cmax) was not
associated with increase in occurrence of AEs.
4 Discussion
Morquio A syndrome is a progressive lysosomal storage
disorder that results from deficiency of the lysosomal
enzyme GALNS, causing broad morbidity and early mor-
tality. Patients with Morquio A syndrome can present with
differing disease manifestations and severity due to the
heterogeneous nature of the disease [4, 10]. Currently, no
treatment options are available that address the biological
causes of Morquio A syndrome, but ERT with recombinant
human GALNS enzyme (elosulfase alfa) may represent a
possible treatment option. This study examined the phar-
macokinetic and pharmacodynamic characteristics of elo-
sulfase alfa 2.0 mg/kg dosing either weekly or every other
week in patients with Morquio A syndrome during MOR-
004, a 24-week, phase III, randomized, double-blind, pla-
cebo-controlled study conducted at 33 study centers in 17
countries.
Data from previous studies of elosulfase alfa support
dosing at 2.0 mg/kg/QW. Prior studies demonstrated that,
compared with elosulfase alfa 1.0, 2.0 mg/kg/QW yielded
higher plasma concentrations of elosulfase alfa and
sustained these concentrations above the Kuptake of the CI-
M6PR for longer [6, 8]. A prior dose-escalation study
showed elosulfase alfa dose-dependent declines in mean
normalized uKS, with the greatest declines observed at
2.0 mg/kg QW, the highest dose tested [7]. The MOR-004
study demonstrated that, compared with placebo, elosulf-
ase alfa 2.0 mg/kg/QW produced statistically significant
differences in 6MWT distance and was associated with
reductions in uKS, whereas the 2.0 mg/kg/QOW dose
reduced uKS but was not associated with significant change
in 6MWT distances [5]. These data support dosing elo-
sulfase alfa at 2.0 mg/kg/QW and suggest that both dose
and frequency of administration may impact outcomes and
decreases in uKS.
Pharmacokinetic parameters were comparable between
the two dosage regimens at week 0. Variability in elo-
sulfase alfa pharmacokinetics among patients was not
explained by patient demographics, as the demographics
characteristics of patients did not appear to correlate with
clearance of elosulfase alfa or other pharmacokinetic
parameters. Although elosulfase alfa has a short plasma
half-life, its intracellular half-life is estimated to be
5–7 days in human Morquio fibroblasts, which supports the
QOW and QW dosing [11]. Pharmacokinetics of elosulfase
alfa are time dependent, as demonstrated by increased
plasma exposure, decreased CL, and prolonged half-life at
week 22 compared with week 0. The time-dependent
change in at least some of the pharmacokinetic parameters
Fig. 4 Elosulfase alfa exposure
and percent change in uKS over
24 weeks. Pharmacokinetic
values are from week 22.
Percent change of uKS is the
percent change in creatinine-
normalized uKS levels between
baseline and week 24. AUClast
area under the plasma
concentration-time curve from
time zero to the time of last
measurable concentration, Cmax
observed maximum plasma
concentration, qow every other
week, uKS urinary keratan
sulfate
Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa 1145
of elosulfase alfa are likely Nab related. All patients in this
study developed antibodies against elosulfase alfa by week
16 of the trial. However, for both dosing groups, there were
no apparent associations between total antibody titer and
clearance of elosulfase alfa, nor were there associations
between total antibody titer and the elosulfase alfa elimi-
nation half-life. The majority of patients developed neu-
tralizing antibodies capable of inhibiting elosulfase alfa
binding to the CI-M6PR in an in vitro assay. At each
assessed time point, NAb positivity was slightly higher in
the QW cohort than in the QOW cohort (Schweighardt
et al., manuscript submitted for publication). At week 22
within the QW group, clear differences in elimination half-
life and CL were noted between NAb-positive and NAb-
negative patients. At week 22 within the QOW group,
NAb-positive and NAb-negative patients had a clear dif-
ference in elimination half-life but the difference in CL
was less pronounced, consistent with the small change in
CL (14 %) observed from week 0 to week 22. For patients
receiving weekly elosulfase alfa, only two patients were
NAb negative at week 24. Both of these two patients tested
positive for NAb during the study, but were no longer
positive at week 24 when these analyses were performed.
These patients demonstrated elosulfase alfa clearance at the
upper range of the values exhibited in NAb-positive
patients and elimination half-life at the lower end.
Although the numbers of NAb-negative patients at week 24
were small (n = 2), these results are consistent with results
observed in the independent elosulfase alfa clinical trial
MOR-002, where again NAb positivity was associated with
prolonged elimination half-life and decreased clearance of
elosulfase alfa [8]. Importantly, these observed alterations
in elosulfase alfa pharmacokinetics were not correlated
with changes in efficacy or safety.
Despite variability in elosulfase alfa exposure between
patients during the trial, there were no associations
observed between exposure and efficacy, pharmacody-
namics, and safety for either dosing group. The change in
patients’ levels of uKS between weeks 0 and 24 was not
correlated with elosulfase alfa clearance at week 22 for
either dosing group. Similarly, changes in patients’ results
for either the 6MWT or the 3MSCT between weeks 0 and
24 were not correlated with elosulfase alfa clearance at
week 22 for either dosing group. Additionally, for patients
in both dosing groups the occurrence of AEs was not
correlated with elosulfase alfa exposure. These results
indicate that the observed variability in elosulfase alfa
exposure in plasma may not translate directly to pharma-
codynamic, efficacy, or safety outcomes in patients, pos-
sibly because these plasma concentrations do not directly
reflect the concentration where the drug is enzymatically
active, at the likely site of action within the intracellular
lysosomal compartment [6]. Although the 24-week
duration of this study did not allow for the assessment of
the long-term effects of elosulfase alfa, a long-term
extension of this study (MOR-005; NCT01415427) and a
patient registry will allow continued monitoring and
assessment of the efficacy and safety of elosulfase alfa
treatment in patients with Morquio A.
Compared with ERTs for other mucopolysaccharidosis
diseases, such as laronidase for MPS I, idursulfase for MPS
II, and galsulfase for MPS VI, the clearance of elosulfase
alfa is about two- to threefold higher, which is in agree-
ment with its two- to fourfold higher dose recommended
for clinical use [12–16]. Enzyme replacement therapies for
MPS diseases generally have a short plasma elimination
half-life, from 26 min for galsulfase to 1.5 to 3.6 h for
laronidase. However, their intracellular or tissue half-life is
much longer, between 1 and 2 days in rat tissue for idur-
sulfase and 5–7 days in human Morquio fibroblasts for
elosulfase alfa [11]. The long intracellular or tissue half-
life supports their weekly dosing recommended for clinical
use as the site of action of these ERTs is within the
intracellular lysosomal compartment.
5 Conclusion
This paper summarized pharmacokinetic characteristics
and their relationship to the demographics, immunogenic
responses, pharmacodynamics, efficacy, and safety of elo-
sulfase alfa observed in patients with Morquio A syndrome
in a phase III trial. Exposure was seen to increase over the
24-week study period in patients who received elosulfase
alfa 2.0 mg/kg either QW or QOW. Variability in elo-
sulfase alfa exposure in plasma appeared not to translate
directly to pharmacodynamic, efficacy, or safety outcomes
in patients, possibly because the drug’s site of action is
within the intracellular lysosomal compartment. In com-
bination with the primary efficacy and safety outcomes of
this trial [5], these data support the dosing of elosulfase alfa
at 2.0 mg/kg/QW in patients with Morquio A.
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